TFF Pharmaceuticals, Inc. Common Stock
TFFP
TFFP was delisted on the 12th of December, 2024.
54 hedge funds and large institutions have $45.1M invested in TFF Pharmaceuticals, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 17 increasing their positions, 17 reducing their positions, and 15 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 17
8% less funds holding
Funds holding: 59 → 54 (-5)
17% less capital invested
Capital invested by funds: $54.5M → $45.1M (-$9.35M)
33% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 15
33% less call options, than puts
Call options by funds: $1.13M | Put options by funds: $1.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CA
Corriente Advisors
Fort Worth,
Texas
|
+$8.66M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$878K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$634K |
| 4 |
JP Morgan Chase
New York
|
+$597K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$578K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$2.02M |
| 2 |
GS
Gagnon Securities
New York
|
-$1.5M |
| 3 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
-$1.34M |
| 4 |
GA
Gagnon Advisors
New York
|
-$1.34M |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$961K |
TFFP Hedge Fund Activity: Q3 2021 in Review
54 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in TFF Pharmaceuticals, Inc. Common Stock (TFFP) for Q3 2021, worth a combined $45.1M — down 17% from $54.5M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of TFFP and 10 opened new positions — a net loss of 5 holders — while 17 trimmed existing stakes and 17 added.
The largest buyer was Corriente Advisors, opening a new position worth an estimated $8.66M. The largest seller was Granite Point Capital Management, exiting entirely with an estimated $2.02M sold.
- 54 institutional investors held TFF Pharmaceuticals, Inc. Common Stock (TFFP) as of Q3 2021, down from 59 in Q2 2021.
- Funds reported $45.1M of TFF Pharmaceuticals, Inc. Common Stock stock for Q3 2021, down 17% quarter-over-quarter.
- 10 funds opened new TFF Pharmaceuticals, Inc. Common Stock positions in Q3 2021 and 15 closed out, a net change of -5 holders.
- The largest TFF Pharmaceuticals, Inc. Common Stock buyer in Q3 2021 was Corriente Advisors, an estimated $8.66M added.
- The largest TFF Pharmaceuticals, Inc. Common Stock seller in Q3 2021 was Granite Point Capital Management, an estimated $2.02M sold.
Based on aggregated 13F filings for Q3 2021.